CURRICULUM VITAE
SALVATORE ODDO

Date of Preparation: May 31, 2022

CONTACT INFORMATION:
Associate Professor of Molecular Biology
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences
University of Messina

Viale Ferdinando Stagno d'Alcontres 31
98166 Messina, Italy

Email Address: salvatore.oddo@unime.it

EDUCATION:

Year	Degree	Discipline	Institution/Location
09/2003 - 07/2005	Ph.D.	Neurobiology and Behavior	University of California Irvine, CA
09/1993 - 07/1999	BS	Biological Sciences – Molecular Biology (*Graduated with first-class honors degree)*	University of Catania, Italy

ACADEMIC APPOINTMENTS:

2020 – Present	Associate Professor, University of Messina, Italy.
08/2015 – 2020	Associate Professor, Arizona State University, School of Life Sciences, Tempe, AZ.
07/2017 – 06/2019	Director of the Interdisciplinary Graduate Program in Neuroscience, Arizona State University, Tempe, AZ.
08/2015 – 06/2019	Adjunct Associate Professor, University of Arizona College of Medicine-Phoenix, Department of Basic Medical Sciences, Phoenix, AZ.
07/2013 – 08/2015	Associate Professor, University of Arizona College of Medicine-Phoenix, Department of Basic Medical Sciences, Phoenix, AZ.
07/2013 – 08/2015	Senior Scientist, Banner Sun Health Research Institute, Sun City, AZ.
07/2008 – 06/2013	Assistant Professor, University of Texas Health Science Center at San Antonio, Department of Physiology, San Antonio, TX.
07/2007 - 06/2008	Assistant Researcher, University of California Irvine, Department of Neurobiology and Behavior, Irvine, CA.
07/2005 - 07/2007	Postdoctoral Researcher, University of California Irvine, Department of Neurobiology and Behavior, Irvine, CA.

NON-ACADEMIC APPOINTMENTS:

2011 – Present	Alzheimer's Drug Discovery Foundation Review Board Member
2018 – 2020	Permanent Member of the NIH Cellular and Molecular Neurodegeneration Study Section
2013 – 2019	Internal Scientific Advisory Committee Member for the Arizona Alzheimer's Consortium
2002 - 2005	Graduate Student Researcher, University of California Irvine, Irvine, CA.
1999 - 2002	Staff Research Associate, University of California Irvine, Irvine, CA.

HONORS AND AWARDS:

12/2018 Edson Endowed Professor in Dementia Research
07/2018 Permanent member of the Cellular and Molecular Neurodegeneration Study Section
05/2013 New Vision Award from the Charleston Conference on Alzheimer's disease.
11/2011 The Presidential Distinguished Junior Research Scholar Award from the University of Texas Health Science Center at San Antonio.
07/2011 The Glenn Award for Research in Biological Mechanisms of Aging. This award included a grant for $60,000.00.
10/2010 Rising Stars Award from The Board of Regents of the University of Texas. This award included a grant for $250,000.00 for equipment expenditures.
08/2009 The Nathan Shock New Investigator Award assigned by the Gerontological Society of America in recognition of innovative and influential publications.
05/2009 University Research Council Grants Program Award, University of Texas Health Science Center at San Antonio.
01/2006 Dean's Award for Postdoctoral Research Excellence, University of California Irvine.
01/2006 Travel Fellowship from the Alzheimer's Association to attend the 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, Spain.
05/2005 AD/PD Award (Alzheimer's Disease and Parkinson's Disease) in Memory of Roberto Cornelli for Young Scientists presenting their work at the AD/PD meeting in Sorrento, Italy 2005.
03/2005 Irvine Medal Fellowship for Excellence in Graduate Research. University of California Irvine.
02/2005 Ralph W. Gerard award for Excellence in the History of Neuroscience. University of California Irvine.
08/2004 McGaugh Award for Excellence in Graduate Research in Neurobiology & Behavior, University of California Irvine.
06/2004 Al Nichols Research Prize in the Neurobiology of Aging for outstanding contributions to the study of brain aging.
01/1992 Merit Scholarship from University of Catania (Italy).

CURRENT RESEARCH GRANTS:

None

COMPLETED RESEARCH GRANTS:

Project #: R01AG061134
Funding Agency: NIH – National Institute on Aging
Title: RIPK1 as a novel kinase involved in the pathogenesis of Alzheimer's disease
Period: 03/2019 - 02/2024 (terminated in 2020 as I moved outside the Country)
Role: Principal Investigator
Grant Detail: The goal of this grant is to dissect the role of this protein kinase in Alzheimer's disease.

Project #: R01AG063454
Funding Agency: NIH – National Institute on Aging
Title: mTOR at the crossroad between aging and Alzheimer's disease
Period: 04/2019 - 02/2024 (terminated in 2020 as I moved outside the Country)
Role: Principal Investigator
Grant Detail: The goal of this grant is to dissect the mechanisms by which aging contributes to Alzheimer's disease.

Project #: 1R01AG057596-01A1
Funding Agency: NIH –National Institute on Aging
Title: Necroptosis as a novel mechanism of neurodegeneration in Alzheimer's disease
Period: 09/2018 - 05/2023

Role: Principal investigator (terminated in 2020 as I moved outside the Country)
Grant detail: The overall goal of this grant is to study the mechanisms of neuronal loss in Alzheimer's disease focusing on necroptosis, a programmed form of cell death.

Project #: 2R01AG037637-07
Funding Agency: NIH – National Institute on Aging
Title: Molecular interplay between Aβ, tau and mTOR: Mechanisms of neurodegeneration
Period: 08/2016 - 07/2021
Role: Principal Investigator (terminated in 2020 as I moved outside the Country)
Grant Detail: The objective of this proposal is to elucidate the role of the mammalian target of rapamycin in the pathogenesis of Alzheimer' disease.

Project #: N/A
Funding Agency: University of Arizona
Title: Brain Aging and Neurodegeneration
Period: 06/2017 - 05/2020
Role: Principal Investigator
Grant detail: This is a subaward from a postdoctoral training grant to study brain aging and neurodegenerative diseases.

Project #: 1R21NS096375-01A1
Funding Agency: NIH – National Institute of Neurological Disorders and Stroke
Title: Tau conditional knockout mice to elucidate the function of tau in the adult brain
Period: 08/2016 - 07/2018 (no cost extension until 07/2019)
Role: Principal Investigator
Grant Detail: The objective of this proposal is to assess the role of tau in the adult brain

Project #: N/A
Funding Agency: Sentinel Oncology
Title: Determine the effects of FS115 and SOL784 on the AD-like pathology in 3xTg-AD mice
Period: 12/2017 - 01/2019
Role: Principal investigator
Grant detail: To determine whether pharmacological inhibition of the ribosomal protein S6 kinase 1 (S6K1) with FS-115 and SOL784 is a valid approach to prevent or slow down the progression of Alzheimer's disease (AD)-like pathology in 3xTg-AD mice.

Project #: N/A
Funding Agency: Arizona Alzheimer's Consortium
Title: A novel mouse model to study neurodegeneration in Alzheimer's disease
Period: 07/2018 - 06/2019
Role: Principal investigator
Grant detail: The main objective of this grant is to develop a new mouse model to study the role of RIPK1 in Alzheimer's disease.

Project #: AARG-17-503765
Funding Agency: Alzheimer's Association
Title: Molecular mechanisms of cognitive decline in Alzheimer's disease
Period: 01/2017-01/2020
Role: Mentor (PI: Antonella Caccamo, Assistant Research Professor in my lab)
Grant Detail: The overall objective of this proposal is to elucidate the role NR4A2 on AD pathogenesis.

Project #: N/A
Funding Agency: Alzheimer's Association
Title: Pim1 inhibition as a therapeutic strategy for Alzheimer's disease

Period: 10/2016 - 09/2019
Role: Mentor (PI: Ramon Velazquez, a postdoctoral fellow in my laboratory)
Grant detail: The main objective of this grant is to perform preclinical studies to test a selective Pim1 inhibitor on AD-like pathology in mice.

Project #: 20150804
Funding Agency: Alzheimer's Drug Discovery Foundation
Title: Testing of selective DYRK1A inhibitors as a novel treatment of AD
Period: 04/2016 - 10/2018
Role: Collaborator (PI: Travis Dunckley)
Grant detail: The goal is to test the therapeutic potential of DYR219 and DYR266, two novel DYRK1A antagonists that we have generated, toward the prevention of cognitive impairment and Alzheimer's disease pathology using the 3xTg-AD mouse model.

Project #: 1606833
Funding Agency: National Science Foundation
Title: Elucidating the molecular mechanisms linking maternal choline supplementation to healthy cognitive aging
Period: 08/2016 - 07/2018
Role: Mentor (PI: Ramon Velazquez, a postdoctoral fellow in my laboratory)
Grant detail: The main objective of this grant is to assess the role of choline administration on cognitive aging.

Project #: N/A
Funding Agency: Arizona Alzheimer's Consortium
Title: Determine the role of necroptosis in Down syndrome
Period: 07/2017 - 06/2018
Role: Mentor (PI: Antonella Caccamo, Assistant Research Professor in my lab)
Grant detail: The main objective of this grant is to study the mechanisms of neurodegeneration in Down syndrome.

Project #: N/A
Funding Agency: Arizona Alzheimer's Consortium
Title: Novel mechanisms of neuronal death in Alzheimer's disease
Period: 07/2017 - 06/2018
Role: Mentor (PI: Caterina Branca, a postdoctoral fellow in my lab)
Grant detail: The objective of this grant is to assess the role of RIPK1 in Alzheimer's disease
Project #: N/A

Funding Agency: Arizona Alzheimer's Consortium
Title: Staging the progression of AD-like pathology in 3xTg-AD mice
Period: 07/2017 - 06/2018
Role: Principal investigator
Grant detail: The main objective of this grant is to characterize the progression of neuropathology and behavioral alterations in 3xTg-AD mice.

Project #: N/A
Funding Agency: Arizona Alzheimer's Consortium
Title: Assessing the role of necroptosis in Alzheimer's disease
Period: 07/2016 - 06/2017
Role: Principal investigator
Project #: N/A

Funding Agency: Arizona Alzheimer's Consortium

Title: Dissecting the role of tau in the adult mouse brain
Period: 07/2015 - 06/2016
Role: Principal investigator

Project #: 1R01AG037637-01
Funding Agency: NIH – National Institute on Aging
Title: Molecular interplay between Aβ, tau and mTOR: Mechanisms of neurodegeneration
Period: 08/2011 - 07/2016
Role: Principal Investigator

Project #: N/A
Funding Agency: NIH - National Institute on Aging
Title: Mechanism of Amyloid-beta mediated mTOR dysregulation in neurodegeneration
Period: 05/2013 - 08/2015
Role: Mentor (PI: Elena Wisely, at the time of the award she was a Ph.D. candidate)

Project #: N/A
Funding Agency: Alzheimer's Drug Discovery Foundation
Title: Reducing mTOR activity as a treatment for Alzheimer's disease
Period: 08/2013 - 07/2015 (no cost extension until 03/2016)
Role: Principal Investigator

Project #: N/A
Funding Agency: Barrow Neurological Institute and Department of Basic Medical Sciences COM-Phoenix
Title: PACAP deficit and the pathogenesis of Alzheimer's disease
Period: 07/2014 - 06/2015
Role: Co-Principal Investigator

Project #: N/A
Funding Agency: Arizona Alzheimer's Consortium
Title: Establishing a transgenic mouse core for the Arizona Alzheimer's Consortium
Period: 07/2014 - 06/2015
Role: Principal investigator

Project #: N/A
Funding Agency: Arizona Alzheimer's Consortium
Title: Elucidating the role of p62 in Alzheimer's disease pathogenesis
Period: 07/2014 - 06/2015
Role: Co-Principal Investigator

Project #: N/A
Funding Agency: Arizona Alzheimer's Consortium
Title: Cognitive decline associated with enduring inflammation in the wake of traumatic brain injury over the rodent lifespan
Period: 07/2014 - 06/2015
Role: Co-Principal Investigator

Project #: N/A
Project #: NRSA award
Funding Agency: NIH - National Institute on Aging
Title: Molecular mechanisms underlying Frontotemporal Lobar Degeneration
Period: 07/2012 - 06/2014
Role: Mentor (PI: David Medina, at the time of the award he was a Ph.D. student)

Project #: N/A
Funding Agency: Charleston Conference on Alzheimer's Disease
Title: Restoring cognition by remotely stimulating selective neuronal networks.
Period: 07/2013 - 06/2014
Role: Principal Investigator

Project #: 2010 OWENS FDN
Funding Agency: The William and Ella Owens Medical Research Foundation
Title: Molecular interplay between Abeta, tau and mTOR: Mechanisms of neurodegeneration
Period: 03/2011 - 06/2013
Role: Principal Investigator

Project #: N/A
Funding Agency: Glenn Foundation
Title: Biological mechanisms of aging
Period: 08/2011 - 07/2013
Role: Principal Investigator

Project #: 2011
Funding Agency: American Federation for Aging Research
Title: β2 adrenergic receptors as mediators of the Aβ-induced cognitive decline.
Period: 07/2011 - 06/2013
Role: Principal Investigator

Project #: NIRG-10-173571
Funding Agency: Alzheimer's Association
Title: The role of chaperone-mediated autophagy in Alzheimer's disease
Period: 10/2010 - 09/2012
Role: Principal Investigator

Project #: RC2AG036613
Funding Agency: NIH - National Institute on Aging
Title: Can Rapamycin Retard Age-Related Diseases?
Period: 10/2009 - 09/2011 (No-cost extension until 09/2012).
Role: Co-Principal Investigator for Project 2

Project #: K99/R00 AG-02972
Funding Agency: NIH - National Institute on Aging
Title: Molecular Mechanisms of Memory Loss in a Transgenic Model of Alzheimer's Disease
Period: 07/2007 - 02/2012
Role: Principal Investigator

Project #: AG013319
Funding Agency: Nathan Shock Center
Title: Elucidating the role of TDP-43 in disease pathogenesis
Period: 07/2010 - 06/2011
Role: Principal Investigator

Project #: N/A
Funding Agency: University of Texas Health Science Center at San Antonio, University Research Council Grants Program Award
Title: Modeling Frontotemporal Lobar Degeneration in Mice.
Period: 04/2009 - 03/2010

Role: Principal Investigator

PUBLICATIONS:
Scopus Author Output: **Total Citations: 21,049; h-index 62**

Peer-Reviewed Research Articles (total 93)
The impact factors are reported for the year when the article was published and were obtained from the Journal home page. The number of citations was obtained from Scopus on May 6, 2022.

1. Engelender s, Stefanis L, **Oddo S**, Bellucci A. Can we treat neurodegenerative proteinopathies by enhancing protein degradation? Movement disorders. 2022, *in press*
   **Journal impact factor: 10.34 Number of times cited: 0

2. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, ….. O'Sullivan TE, **Oddo S**, Oehme I, … Tong CK. Guidelines for the use and interpretation of assays for monitoring autophagy, 4th edition. Autophagy. 2021 Jan;17(1):1-382
   **Journal impact factor: 16.016 Number of times cited: 398

3. Vartak RS, Rodin A, **Oddo S.** Differential activation of the mTOR/autophagy pathway predicts cognitive performance in APP/PS1 mice. Neurobiol Aging. 2019 Nov;83:105-113
   **Journal impact factor: 5.153 Number of times cited: 14

4. Velazquez R, Ferreira E, Knowles S, Fux C, Rodin A, Winslow W, **Oddo S**. Lifelong choline supplementation ameliorates Alzheimer's disease pathology and associated cognitive deficits by attenuating microglia activation. Aging Cell. 2019 Sep 27:e13037
   **Journal impact factor: 7.6 Number of times cited: 34

5. Velazquez R, Meechoovet B, Ow A, Foley C, Shaw A, Smith B, **Oddo** S, Hulme C, Dunckley T. Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice. Mol Neurobiol. 2019 Jun 25. doi: 10.1007/s12035-019-01684-9. [Epub ahead of print]
   **Journal impact factor: 5.076 Number of times cited: 8

6. Velazquez R, Ferreira E, Winslow W, Dave N, Piras I, Naymik M, Huentelman MJ, Tran A, Caccamo A, and **Oddo S.** Maternal choline supplementation ameliorates Alzheimer's disease pathology by reducing brain homocysteine levels across multiple generations. Mol Psychiatry. 2019 Jan 8.
   **Journal impact factor: 14.49 Number of times cited: 22

7. Belfiore R, Rodin A, Ferreira E, Velazquez R, Branca C, Caccamo A, **Oddo S**. Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice. Aging Cell. 2019 Feb;18(1):e12873.
   **Journal impact factor: 6.7 Number of times cited: 83

8. Velazquez R, Ferreira E, Tran A, Turner EC, Belfiore R, Branca C, and **Oddo S**. Acute tau knockdown in the hippocampus of adult mice causes learning and memory deficits. Aging Cell. 2018 May 10:e12775. doi: 10.1111/acel.12775.
   **Journal impact factor: 6.7 Number of times cited: 34

9. Branca C, Ferreira E, Nguyen TV, Doyle K, Caccamo A, **Oddo S**. Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer's disease. Hum Mol Genet. 2017 Dec 15;26(24):4823-4835.
   **Journal impact factor: 5.34 Number of times cited: 46

10. Velazquez A, Tran A, Ishimwe E, Denner L, Dave N, **Oddo S**[#], Dineley KT[#]. Central insulin dysregulation and energy dyshomeostasis in two models of Alzheimer's disease. Neurobiol Aging. 2017 Oct;58:1-13.
    **Journal impact factor: 5.12 Number of times cited: 49
    # Co-senior authors

11. Branca C, Shaw DM, Belfiore R, Gokhale V, Shaw AY, Foley C, Smith B, Hulme C, Dunckley T, Meechoovet B, Caccamo A, and **Oddo S.** Dyrk1 inhibition improves Alzheimer's disease-like pathology. Aging Cell. 2017 Oct;16(5):1146-1154.
    **Journal impact factor: 6.71 Number of times cited: 50

12. Branca C and **Oddo S**. Paving the way for new clinical trials for Alzheimer's disease. Biological Psychiatry. 2017 Jan 15;81(2):88-89.
    **Journal impact factor: 11.21 Number of times cited: 2

13. Norambuena A, Wallrabe H, McMahon L, Silva A, Swanson E, Khan SS, Baerthlein D, Kodis E, **Oddo S**, Mandell JW, Bloom GS. mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. Alzheimers Dement. 2017 Feb;13(2):152-167.
    **Journal impact factor: 11.62 Number of times cited: 45

14. Velazquez R, Shaw DM, Caccamo A, **Oddo S**. Pim 1 inhibition as a novel therapeutic strategy for Alzheimer's disease. Mol Neurodegener. 2016 Jul 13;11(1):52.
    **Journal impact factor: 6.5 Number of times cited: 20

15. Ferreira E, Shaw DM, **Oddo S**. Identification of learning-induced changes in protein networks in the hippocampi of a mouse model of Alzheimer's disease. Transl Psychiatry. 2016 Jul 5;6(7):e849.
    **Journal impact factor: 5.6 Number of times cited: 10

16. Caccamo A, Branca C, Talboom JS, Shaw DM, Turner D, Ma L, Messina A, Huang Z, We J, **Oddo S**. Reducing ribosomal protein S6 kinase 1 expression improves spatial memory and synaptic plasticity in a mouse model of Alzheimer's disease. J Neurosci. 2015 Oct 14;35(41):14042-56.
    **Journal impact factor: 6.3 Number of times cited: 54

17. Talboom JS, Velazquez R, **Oddo S**. The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer's disease. NPJ Aging Mech Dis. 2015 Oct 15;1:15008. doi: 10.1038/npjamd.2015.8.
    **Journal impact factor: N/A Number of times cited: 44

18. Mastroeni D, Delvaux E, Nolz J, Tan Y, Grover, A, **Oddo S**, Coleman P. Aberrant Intracellular Localization of H3k4me3 Demonstrates an Early Epigenetic Phenomenon in Alzheimer's Disease. Neurobiol Aging. 2015 Dec;36(12):3121-9.
    **Journal impact factor: 5.013 Number of times cited: 31

19. Caccamo A, Shaw DM, Guarino F, Messina A, Walker AW, **Oddo S.** Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDa C-terminal fragment of TDP-43. Hum Mol Genet. 2015 Aug 15;24(16):4625-35.
    **Journal impact factor: 6.3 Number of times cited: 22

20. Richardson A, Galvan V, Lin AL, **Oddo S.** How Longevity Research Can Lead to Therapies for Alzheimer's Disease: The Rapamycin Story. Exp Gerontol. 2015 Aug;68:51-8.
    **Journal impact factor: 3.529 Number of times cited: 81

21. Branca C, Wisely EV, Hartman LK, Caccamo A, **Oddo S.** Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. Neurobiol of Aging. 2014 Dec;35(12):2726-35.
    **Journal impact factor: 6.189 Number of times cited: 38

22. Caccamo A, De Pinto V, Messina A, Branca C, **Oddo S**. Genetic reduction of mTOR ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J Neurosci. 2014 Jun 4;34(23):7988-98.
    **Journal impact factor: 6.9 Number of times cited: 127

23. Wisely EV, Xiang YK, **Oddo S**. Genetic suppression of β2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies. Hum Mol Genet. 2014 Aug 1;23(15):4024-34.
    **Journal impact factor: 7.692 Number of times cited: 17

24. Orr ME, Salinas A, Buffenstein R, **Oddo S**. Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. Neurobiol Aging. 2014 Jun;35(6):1233-42.
    **Journal impact factor: 6.189 Number of times cited: 55

25. Edrey YH, **Oddo S**, Cornelius C, Caccamo A, Calabrese V, Buffenstein R. Oxidative damage and amyloid-β metabolism in brain regions of the longest-lived rodents. J Neurosci Res. 2014 Feb;92(2):195-205.
    **Journal impact factor: 2.974 Number of times cited: 29

26. Orr ME and **Oddo S**. Autophagic/lysosomal dysfunction in Alzheimer's disease. Alzheimers Res Ther. 2013 Oct 29;5(5):53.
    **Journal impact factor: 4.390 Number of times cited: 109

27. Medina DX, Orr ME, **Oddo S.** Accumulation of C-terminal fragments of TDP-43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice. Neurobiol Aging. 2014 Jan;35(1):79-87.
    **Journal impact factor: 6.189 Number of times cited: 28

28. Edrey YH, Medina DX, Gaczynska M, Osmulski PA, **Oddo S,** Caccamo A, Buffenstein R. Amyloid beta and the longest-lived rodent: the naked mole-rat as a model for natural protection from Alzheimer's disease. Neurobiol Aging. 2013 Oct;34(10):2352-60.
    **Journal impact factor: 6.189 Number of times cited: 53

29. Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda MF, Silva AJ, **Oddo S**. mTOR regulates tau phosphorylation and degradation: Implications for Alzheimer's disease and other tauopathies. Aging Cell. 2013 Jun;12(3):370-80.
    **Journal impact factor: 7.15 Number of times cited: 246

30. Wang D, Fu Q, Zhou Y, Xu B, Shi Q, Igwe B, Matt L, Hell JW, Wisely EV, **Oddo S**, Xiang YK. β2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer's disease models. J Biol Chem. 2013 Apr 12;288(15):10298-307.
    **Journal impact factor: 4.773 Number of times cited: 69

31. Caccamo A, Medina DX, **Oddo S.** Glucocorticoids exacerbate cognitive deficits in TDP-25 transgenic mice via a glutathione-mediated mechanism: Implications for aging, stress and TDP-43 proteinopathies. J Neurosci. 2013 Jan 16;33(3):906-13.
    **Journal impact factor: 7.115 Number of times cited: 29

32. Yan XX, Cai Y, Shelton J, Deng SH, Luo XG, **Oddo S**, LaFerla FM, Cai H, Rose GM, Patrylo PR. Chronic Temporal Lobe Epilepsy Is Associated with Enhanced Alzheimer-Like Neuropathology in 3xTg-AD Mice. PLoS One. 2012;7(11):e48782.
    **Journal impact factor: 4.092 Number of times cited: 42

33. Klionsky DJ, Abdalla FC, Abeliovich H, ….. Oberley TD, **Oddo S,** Ogawa M, … Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 April. 8(4):445-544.
    **Journal impact factor: 7.453 Number of times cited: 2,706

34. Takamura A, Sato Y, Watabe D, Okamoto Y, Nakata T, Kawarabayashi T, **Oddo S**, LaFerla FM, Shoji M, Matsubara E. Sortilin is required for toxic action of Aβ oligomers (AβOs): Extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways. Life Sci. 2012 Dec 10;91(23-24):1177-86.
    **Journal impact factor: 2.451 Number of times cited: 21

35. Walker MP, LaFerla FM, **Oddo S**, Brewer GJ. Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease. Age (Dordr). 2013 Jun;35(3):519-31.
    **Journal impact factor: 6.28 Number of times cited: 70

36. Cotella D, Hernandez Enriquez B, Wu X, Li R, Pan Z, Leveille J, Link C, **Oddo S**, and Sesti F. Toxic role of K+ channel oxidation in mammalian brain (in press). J Neurosci. 2012 Mar 21;32(12):4133-4144.
    **Journal impact factor: 7.27 Number of times cited: 60

37. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A, **Oddo S.** Life-long rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and NMDA signaling. Aging Cell. 2012 Apr;11(2):326-35.
    **Journal impact factor: 7.15 Number of times cited: 152

38. **Oddo S.** The role of mTOR signaling in Alzheimer disease. Frontiers in Bioscience (Schol Ed). 2012 Jan 1;4:941-52.
    **Journal impact factor: 4.05 Number of times cited: 133

39. Caccamo A, Majumder S, **Oddo S.** Cognitive decline typical of FTLD in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43. Am J Pathol. 2012 Jan;180(1):293-302. Epub 2011 Nov 7.
    **Journal impact factor: 5.22 Number of times cited: 39

40. Majumder S, Richardson A, Strong R, **Oddo S.** Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One. 2011;6(9):e25416. Epub 2011 Sep 28.
    **Journal impact factor: 4.41 Number of times cited: 285

41. Cai Y, Zhang XM, Macklin LN, Cai H, Luo XG, **Oddo S,** LaFerla FM, Struble RG, Rose GM, Patrylo PR, Yan XX. BACE1 Elevation is Involved in Amyloid Plaque Development in the Triple Transgenic Model of Alzheimer's Disease: Differential Aβ Antibody Labeling of Early-Onset Axon Terminal Pathology. Neurotox Res. 2012 Feb;21(2):160-74. Epub 2011 Jul 2.
    **Journal impact factor: 3.01 Number of times cited: 37

42. Bianchi FT, Camera P, Ala U, Imperiale D, Migheli A, Boda E, Tempia F, Berto G, Bosio Y, **Oddo S,** LaFerla FM, Taraglio S, Dotti CG, Di Cunto F. The Collagen Chaperone HSP47 Is a New Interactor of APP that Affects the Levels of Extracellular Beta-Amyloid Peptides. PLoS One. 2011 Jul;6(7):22370-22370.

**Journal impact factor: 4.41 Number of times cited: 8

43. Caccamo A, Maldonado MA, Majumder S, Medina DX, Holbein W, Magrí A, **Oddo S.** Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem. 2011 Mar;286(11):8924-8932.
**Journal impact factor: 5.33 Number of times cited: 129

44. Medina DX, Caccamo A, **Oddo S.** Methylene blue reduces Aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011 Mar;21(2):140-149.
**Journal impact factor: 4.74 Number of times cited: 185

45. Caccamo A, Maldonado MA, Bokov AF, Majumder S, **Oddo S.** CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2010 Dec;107(52):22687-22692.
**Journal impact factor: 9.77 Number of times cited: 187

46. Caccamo A, Magrí A, **Oddo S.** Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to Aβ oligomers accumulation. Mol Neurodegener. 2010 Nov;5:51-51.
**Journal impact factor: 5.36 Number of times cited: 27

47. Nakashima AS, **Oddo S,** LaFerla FM, Dyck RH. Experience-dependent regulation of vesicular zinc in male and female 3xTg-AD mice. Neurobiol Aging. 2010 Apr;31(4):605-613.
**Journal impact factor: 6.63 Number of times cited: 15

48. Caccamo A, Majumder S, Richardson A, Strong R, **Oddo S.** Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem. 2010 Apr;285(17):13107-13120.
**Journal impact factor: 5.33 Number of times cited: 647

49. Bryleva EY, Rogers MA, Chang CC, Buen F, Harris BT, Rousselet E, Seidah NG, **Oddo S,** LaFerla FM, Spencer TA, Hickey WF, Chang TY. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A. 2010 Feb;107(7):3081-3086.
**Journal impact factor: 9.77 Number of times cited: 137

50. Caccamo A, Majumder S, Deng JJ, Bai Y, Thornton FB, **Oddo S.** Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem. 2009 Oct;284(40):27416-27424.
**Journal impact factor: 5.33 Number of times cited: 123

51. **Oddo S,** Caccamo A, Cheng D, LaFerla FM. Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. Brain Pathol. 2009 Jul;19(3):421-430.
**Journal impact factor: 4.74 Number of times cited: 28

52. Ouellet M, Emond V, Chen CT, Julien C, Bourasset F, **Oddo S,** LaFerla F, Bazinet RP, Calon F. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: An in situ cerebral perfusion study. Neurochem Int. 2009 Dec;55(7):476-82. Epub 2009 May 13.
**Journal impact factor: 3.60 Number of times cited: 151

53. Guan H, Liu Y, Daily A, Police S, Kim MH, **Oddo S,** LaFerla FM, Pauly JR, Murphy MP, Hersh LB. Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease. J Neurosci Res. 2009 May;87(6):1462-1473.
**Journal impact factor: 2.96 Number of times cited: 67

54. McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, **Oddo S,** Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 2009 Apr;34(1):163-177.
    **Journal impact factor: 5.12 Number of times cited: 207

55. Bourasset F, Mélissa O, Tremblay C, Julien C, Do TM, **Oddo S,** LaFerla F, Calon F. Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. Neuropharmacology. 2009 Mar;56(4):808-813.
    **Journal impact factor: 4.68 Number of times cited: 78

56. Nuntagij P, **Oddo S,** LaFerla FM, Kotchabhakdi N, Ottersen OP, Torp R. Amyloid deposits show complexity and intimate spatial relationship with dendrosomatic plasma membranes: an electron microscopic 3D reconstruction analysis in 3xTg-AD mice and aged canine. J Alzheimers Dis. 2009 Feb;16(2):315-323.
    **Journal impact factor: 4.26 Number of times cited: 19

57. Gulinello M, Gertner M, Mendoza G, Schoenfeld BP, **Oddo S,** LaFerla F, Choi CH, McBride SM, Faber DS. Validation of a 2-day water maze protocol in mice. Behav Brain Res. 2009 Jan;196(2):220-227.
    **Journal impact factor: 3.34 Number of times cited: 69

58. Janelsins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, **Oddo S,** LaFerla FM, Callahan LM, Federoff HJ, Bowers WJ. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol. 2008 Dec;173(6):1768-1782.
    **Journal impact factor: 5.22 Number of times cited: 172

59. **Oddo S,** Caccamo A, Tseng B, Cheng D, Vasilevko V, Cribbs DH, LaFerla FM. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci. 2008 Nov;28(47):12163-12175.
    **Journal impact factor: 7.27 Number of times cited: 115

60. Rodríguez JJ, Jones VC, Tabuchi M, Allan SM, Knight EM, LaFerla FM, **Oddo S,** Verkhratsky A. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One. 2008 Aug;3(8):2935.
    **Journal impact factor: 4.41 Number of times cited: 281

61. Lopez JR, Lyckman A, **Oddo S,** LaFerla FM, Querfurth HW, Shtifman A. Increased intraneuronal resting [Ca2+] in adult Alzheimer's disease mice. J Neurochem. 2008 Apr;105(1):262-271.
    **Journal impact factor: 4.38 Number of times cited: 124

62. **Oddo S.** The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med. 2008 Apr;12(2):363-373.
    **Journal impact factor: 4.60 Number of times cited: 183

63. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, **Oddo S,** LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008 May 1;1207:225-36. Epub 2008 Feb 16.
    **Journal impact factor: 2.62 Number of times cited: 181

64. Maezawa I, Hong HS, Liu R, Wu CY, Cheng RH, Kung MP, Kung HF, Lam KS, **Oddo S,** LaFerla FM, Jin LW. Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem. 2008 Jan;104(2):457-468.
    **Journal impact factor: 4.38 Number of times cited: 182

65. Giménez-Llort L, Blázquez G, Cañete T, Johansson B, **Oddo S,** Tobeña A, LaFerla FM, Fernández-Teruel A. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev. 2007;31(1):125-47.
    **Journal impact factor: 9.01 Number of times cited: 186

66. Carroll JC, Rosario ER, Chang L, Stanczyk FZ, **Oddo S,** LaFerla FM, Pike CJ. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci. 2007 Nov;27(48):13357-13365.
    **Journal impact factor: 7.27 Number of times cited: 241

67. Cole AR, Noble W, van Aalten L, Plattner F, Meimaridou R, Hogan D, Taylor M, LaFrancois J, Gunn-Moore F, Verkhratsky A, **Oddo S,** LaFerla F, Giese KP, Dineley KT, Duff K, Richardson JC, Yan SD, Hanger DP, Allan SM, Sutherland C. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem. 2007 Nov;103(3):1132-1144.
    **Journal impact factor: 4.38 Number of times cited: 134

68. Yamasaki TR, Blurton-Jones M, Morrissette DA, Kitazawa M, **Oddo S,** LaFerla FM. Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci. 2007 Oct;27(44):11925-11933.
    **Journal impact factor: 7.27 Number of times cited: 123

69. Clinton LK, Billings LM, Green KN, Caccamo A, Ngo J, **Oddo S,** McGaugh JL, LaFerla FM. Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis. 2007 Oct;28(1):76-82.
    **Journal impact factor: 5.12 Number of times cited: 209

70. **Oddo S,** Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem. 2007 Aug;102(4):1053-1063.
    **Journal impact factor: 4.38 Number of times cited: 71

71. LaFerla FM, Green KN, **Oddo S.** Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007 Jul;8(7):499-509.
    **Journal impact factor: 29.51 Number of times cited: 1,508

72. Caccamo A, **Oddo S,** Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol. 2007 May;170(5):1669-1675.
    **Journal impact factor: 5.22 Number of times cited: 179

73. Stutzmann GE, Smith I, Caccamo A, **Oddo S,** Parker I, LaFerla F. Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer's mouse models. Ann N Y Acad Sci. 2007 Feb;1097:265-277.
    **Journal impact factor: 2.85 Number of times cited: 93

74. **Oddo S,** Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem. 2006 Dec;281(51):39413-39423.
    **Journal impact factor: 5.33 Number of times cited: 259

75. Rosario ER, Carroll JC, **Oddo S,** LaFerla FM, Pike CJ. Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J Neurosci. 2006 Dec;26(51):13384-13389.

**Journal impact factor: 7.27 Number of times cited: 122

76. Stutzmann GE, Smith I, Caccamo A, **Oddo S,** LaFerla FM, Parker I. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci. 2006 May;26(19):5180-5189.
**Journal impact factor: 7.27 Number of times cited: 253

77. Caccamo A, **Oddo S,** Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006 Mar;49(5):671-682.
**Journal impact factor: 14.03 Number of times cited: 360

78. **Oddo S,** LaFerla FM. The role of nicotinic acetylcholine receptors in Alzheimer's disease. J Physiol Paris. 2006 Mar;99(2-3):172-179.
**Journal impact factor: 3.03 Number of times cited: 115

79. **Oddo S,** Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem. 2006 Jan;281(3):1599-1604.
**Journal impact factor: 5.33 Number of times cited: 348

80. **Oddo S,** Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol. 2006 Jan;168(1):184-194.
**Journal impact factor: 5.22 Number of times cited: 200

81. Janelsins MC, Mastrangelo MA, **Oddo S,** LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation. 2005 Oct;2:23-23.
**Journal impact factor: 5.79 Number of times cited: 187

82. Kitazawa M, **Oddo S,** Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci. 2005 Sep;25(39):8843-8853.
**Journal impact factor: 7.27 Number of times cited: 513

83. Smith IF, Hitt B, Green KN, **Oddo S,** LaFerla FM. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem. 2005 Sep;94(6):1711-1718.
**Journal impact factor: 4.38 Number of times cited: 129

84. Caccamo A, **Oddo S,** Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging. 2005 May;26(5):645-654.
**Journal impact factor: 5.12 Number of times cited: 274

85. LaFerla FM, **Oddo S.** Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med. 2005 Apr;11(4):170-176.
**Journal impact factor: 10.31 Number of times cited: 341

86. Billings LM, **Oddo S,** Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005 Mar;45(5):675-688.
**Journal impact factor: 14.03 Number of times cited: 1,007

87. **Oddo S,** Caccamo A, Green KN, Liang K, Tran L, Chen Y, Leslie FM, LaFerla FM. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2005 Feb;102(8):3046-3051.
**Journal impact factor: 9.77 Number of times cited: 166

88. **Oddo S,** Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004 Aug;43(3):321-332.
**Journal impact factor: 14.03 Number of times cited: 719

89. Rissman RA, Poon WW, Blurton-Jones M, **Oddo S,** Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest. 2004 Jul;114(1):121-130.
**Journal impact factor: 14.15 Number of times cited: 445

90. Shakkottai VG, Chou CH, **Oddo S,** Sailer CA, Knaus HG, Gutman GA, Barish ME, LaFerla FM, Chandy KG. Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest. 2004 Feb;113(4):582-590.
**Journal impact factor: 14.15 Number of times cited: 85

91. **Oddo S,** Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 2003 Dec;24(8):1063-1070.
**Journal impact factor: 6.63 Number of times cited: 721

92. **Oddo S,** Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003 Jul;39(3):409-421.
**Journal impact factor: 14.03 Number of times cited: 3,013

93. Sugarman MC, Yamasaki TR, **Oddo S,** Echegoyen JC, Murphy MP, Golde TE, Jannatipour M, Leissring MA, LaFerla FM. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A. 2002 Apr;99(9):6334-6339.
**Journal impact factor: 9.77 Number of times cited: 94

Book Chapters

1. **Oddo S** and Kitazawa M. Genetically modified rodent models: a new generation of translational cognitive science. The Maze Book, edited by Heather Bimonte-Nelson. Humana Press; 2015. p. 259 – 283.

2. **Oddo S.** Animal models of Alzheimer's disease: Plaques, tangles and memory decline. In: A multidisciplinary approach to dissect the Alzheimer Pathology, edited by Roberto Dominici and Ida Biunno. Transworld Research Network; 2008. p. 79 - 82.

3. **Oddo S.** and LaFerla FM. Amyloid plaques and neurofibrillary tangles in a triple transgenic model: qualitative similarities with human Alzheimer's neuropathology. In: Recent progress in Alzheimer's and Parkinson's diseases, edited by Israel Hanin, Ramon Cacabelos, and Abraham Fisher. Taylor & Francis; 2005. p. 111 - 116.

PROFESSIONAL ARTICLES ABOUT MY PUBLISHED WORK:

12/2006 Nature Medicine 12, 762 (2006). A transgenic triple scores a home run.

11/2005 Nature Medicine 11, 259 (2005). Smoking out Alzheimer's disease.
06/2004 Science 305, 762 (2004). Untangling Alzheimer's by pairing plaques bolsters amyloid theory.
06/2004 Science News 166, 83 (2004). Stopping Alzheimer's: antibody thwarts disease in mice.
05/2004 Neuron 43, 293-299 (2004). Clearing tau pathology with Abeta immunotherapy - reversible and irreversible stages revealed.
05/2004 Nature Reviews Neuroscience 5, 259 (2004). Hyperexcitability induces ataxia.
03/2004 Lancet (Neurology) 3, 576 (2004). Mouse model provides support for the amyloid cascade hypothesis.
04/2003 Nature Reviews Neuroscience 4, 701 (2003). Mighty Mouse.

INVITED TALKS AT MEETINGS, ACADEMIC INSTITUTIONS AND PHARMACEUTICAL COMPANIES:

06/2022 mTOR/S6K1 at the crossroad between aging and Alzheimer's disease. 15th Word Congress on Inflammation. Rome, Italy. **Details:** *Invited by Emanuela Esposito, Ph.D.*

10/2020 Dissecting the Role of mTOR Signaling in Alzheimer's Disease. Department of Biology, University of Alabama Birmingham, Birmingham, AL. **Details**: *Invited by Steven Austad, Ph.D.*

04/2019 Nrf2 at the crossroad between aging and Alzheimer's disease. Experimental Biology meeting, Orlando, FL. **Details:** *Invited by Karyn Hamilton, Ph.D*.

02/2019 mTOR and necroptosis in Alzheimer's disease: Partners in crime. Department of Medical and Molecular Genetics, Indiana University School of Medicine. Indianapolis, IN. **Details:** *Invited by Bruce Lamb, Ph.D*.

02/2019 mTOR and necroptosis in Alzheimer's disease: Partners in crime. University of Southern California, Los Angeles, CA. **Details:** *Invited by Jeff Chen, Ph.D.*

02/2019 mTOR and necroptosis in Alzheimer's disease: Partners in crime. Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta, GA. **Details:** *Invited by Xinyun Li, Ph.D.*

11/2018 Necroptosis activation in Alzheimer's disease. Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA. **Details:** *Invited by Peter Baas, Ph.D*.

10/2018 mTOR/S6K1 at the crossroad between aging and Alzheimer's disease. Regional Healthy Aging and Dementia Research Symposium. Lubbock, TX. **Details:** *Invited by Hemachandra Reddy, Ph.D*.

06/2018 Aging and neurodegeneration: The mTOR connection. The 2018 Nathan Shock Centers Bi-Annual Directors' Symposium. Philadelphia, PA. **Details**: *Invited by Mrs. Odette van der Willik*

05/2018 mTOR and necroptosis in Alzheimer's disease: Partners in crime. Aging and Brain Symposium, San Antonio, TX. **Details**: *Invited by Miranda Orr, Ph.D.*

01/2018 Dissecting the role of mTOR and necroptosis in Alzheimer's disease. Neurology Grand Rounds, University of Arizona, Tucson, AZ. **Details**: *Invited by Anita Koshy, Ph.D.*

01/2018 Dissecting the role of mTOR and necroptosis in Alzheimer's disease. Department of Basic Medical Sciences, University of Arizona, College of Medicine-Phoenix, Phoenix, AZ. **Details**: *Invited by Ronald Hammer, Ph.D.*

11/2017 Necroptosis activation in Alzheimer's disease. Regulated Necrosis: Pathways and Mechanisms Meeting, The Banbury Center at Cold Spring Harbor Laboratory. Lloyd Harbor, NY. **Details**: *Invited by Douglas Green, Ph.D.*

10/2017 Dissecting the role of mTOR and necroptosis in neurodegeneration. Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University. New York, NY. **Details**: *Invited by Ottavio Arancio, Ph.D.*

10/2017 Dissecting the role of mTOR and necroptosis in neurodegeneration. University of Oklahoma Health Science Center. Oklahoma City, OK. **Details**: *Invited by Arlan Richardson, Ph.D.*

08/2017 Dissecting the role of mTOR and necroptosis in neurodegeneration. Denali Therapeutics, San Francisco, CA. **Details**: *Invited by Jonas Hannestad, Ph.D.*

04/2017 Dissecting the role of mTOR and necroptosis in neurodegeneration: Therapeutic implications for Alzheimer's disease. Roche Pharmaceutical, Basel, Switzerland. **Details**: *Invited by Kelly Bales, Ph.D.*

09/2016 mTOR at the crossroad between aging and Alzheimer's disease. University of Arizona, Graduate Interdisciplinary program. Tucson, AZ. **Details**: *Invited by Daniela Zarnescu, Ph.D.*

07/2016 Mechanisms of Neurodegeneration in Alzheimer's disease. Department of Biomedical and Biotechnological Sciences. University of Catania, Italy. **Details:** *Invited by Vito De Pinto, Ph.D.*

03/2016 Alzheimer's disease and aging: The mTOR connection. New York State Institute for Basic Research. Staten Island, NY. **Details:** *Invited by Cheng-Xin Gong, M.D.*

02/2016 The mammalian target of rapamycin at the crossroad between Alzheimer's disease and diabetes. The 11th International Symposium on Geriatrics and Gerontology, Morioka, Obu, Aichi, Japan. **Details:** *Invited by Katsuhiko Yanagisawa, M.D.*

11/2015 The mammalian target of rapamycin at the crossroad between aging and Alzheimer's disease. Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston TX. **Details:** *Invited by Anson Pierce, Ph.D.*

09/2015 mTOR signaling links Aβ and tau to cognitive decline: Evidence from animal models. School of Life Sciences, Arizona State University, Tempe, AZ. **Details:** *Invited by Jeanne Wilson-Rawls, Ph.D.*

09/2015 mTOR signaling links Aβ and tau to cognitive decline: Evidence from animal models. The Biodesign Institute at Arizona State University, Arizona State University, Tempe, AZ. **Details:** *Invited by Marco Mangone, Ph.D.*

04/2015 Molecular Interplay Among mTOR, Aβ and tau: Therapeutic Implications for Alzheimer's Disease. Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA. **Details***: Invited by Kim Green, Ph.D.*

02/2015 Chemogenetic tools to remotely stimulate neuronal networks in Alzheimer's disease. Charleston Conference on Alzheimer's disease, Charleston, SC. **Details:** *Invited by Joseph Helpern, Ph.D.*

08/2014 mTOR plays a key role in AD pathogenesis. Barrow Neurological Institute Neuroscience Conference, Phoenix, AZ. **Details**: *Invited by Pengcheng Han, Ph.D.*

04/2014 Dissecting the role of mTOR in Alzheimer's disease. Department of Neuroscience, Rosalind Franklin University, Chicago, IL. **Details:** *Invited by Beth Stutzmann, Ph.D.*

03/2014 mTOR signaling links Aβ and tau to cognitive decline: Evidence from animal models. Department of Psychology, Arizona State University, Tempe, AZ. **Details***: Invited by Federico Sanabria, Ph.D.*

01/2014 mTOR signaling links Aβ and tau to cognitive decline: Evidence from animal models. Department of Basic Medical Sciences, University of Arizona, College of Medicine-Phoenix, Phoenix, AZ. **Details:** *Invited by Aparna Sertil, Ph.D.*

12/2013 mTOR signaling links Aβ and tau to cognitive decline: Evidence from animal models. Department of Biology, University of Virginia, Charlottesville, VA. **Details:** *Invited by George Bloom, Ph.D.*

10/2013 Dissecting the role of mTOR in Alzheimer's disease. Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY. **Details:** *Invited by Masuo Ohno, Ph.D.*

09/2013 Molecular Interplay Among mTOR, Aβ and tau: Therapeutic Implications for Alzheimer's Disease. 7th Neurodegenerative Conditions Research and Development, Boston, MA (Invited Speaker).

06/2013 Glucocorticoids exacerbate cognitive deficits in TDP-25 transgenic mice via a glutathione-mediated mechanism: implications for aging, stress and TDP-43 proteinopathies. American Aging Association 42nd Annual Meeting, Baltimore, MD (Invited Speaker).

05/2013 Rapamycin as a Potential Therapeutic for Alzheimer's Disease. Translating Natural Products into Drugs for Alzheimer's and Neurodegenerative Disease. The New York Academy of Sciences, New York (Invited Speaker).

12/2012 Molecular interplay among Aβ, tau and mTOR: Therapeutic implications for Alzheimer's disease. Dip. di Scienze Biologiche, Geologiche e Ambientali, University of Catania, Italy. ***Details:*** *Invited by Vito De Pinto, Ph.D.*

11/2012 Molecular interplay among Aβ, tau and mTOR: Therapeutic implications for Alzheimer's disease. Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, Baltimore, MD. ***Details:*** *Invited by Danna Zimmer, Ph.D.*

11/2012 Molecular interplay among Aβ, tau and mTOR: Therapeutic implications for Alzheimer's disease. Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA. ***Details:*** *Invited by Xiao-Feng Yang, M.D., Ph.D.*

10/2012 Molecular interplay among Aβ, tau and mTOR in Alzheimer's disease: Therapeutic implications. Department of Biochemistry, University of Texas Health Science Center at San Antonio, TX. ***Details****: Invited by Bruce Nicholson, Ph.D.*

09/2012 The Role of mTOR Signaling in Alzheimer's Diseases: Therapeutic Implications. 6th Neurodegenerative Conditions Research and Development, San Francisco, CA (Invited Speaker).

09/2012 The role of mTOR in Alzheimer's disease. Psychiatry and Neuroscience Center, French National Institute of Health and Medical Research (Inserm). ***Details:*** *Invited by Christian Neri, Ph.D.*

08/2012 Molecular interplay among Aβ, tau and mTOR in Alzheimer's disease. The Barshop Institute for Longevity and Aging Studies, San Antonio, TX. ***Details:*** *Invited by Carlos Orihuela, Ph.D. and Jim Nelson, Ph.D.*

05/2012 The role of mTOR in Alzheimer's disease: Lessons from animal models. Banner Sun Health Research Institute, Phoenix, AZ. ***Details:*** *Invited by Eric Reiman, M.D.*

05/2012 The role of mTOR in Alzheimer's disease: Lessons from animal models. 43th Annual American Society for Neurochemistry meeting. Baltimore, MD (Invited speaker).

10/2011 The role of mTOR in Alzheimer's disease. Department of Neuroscience, Mayo Clinic Florida. Jacksonville, FL. **Details:** *Invited by Malcolm Leissring, Ph.D.*

09/2011 Molecular interplay between Aβ, tau and mTOR: Mechanisms of neurodegeneration. 5th Neurodegenerative Conditions Research and Development, San Francisco, CA (Invited Speaker).

06/2011 Molecular interplay between Aβ, tau and mTOR: Mechanisms of neurodegeneration. Lilly UK, Windlesham, UK. ***Details:*** *Invited by Mike Hutton, Ph.D.*

07/2010 Molecular interplay between Abeta, tau and mTOR: Mechanisms of neurodegeneration. The International Conference on Alzheimer's Disease, Honolulu, HI (Invited Speaker).

05/2010 The role of mTOR in neurodegeneration. Aging and TOR Signaling meeting, Ann Arbor, MI. ***Details:*** *Invited by Susan V. Brooks, Ph.D.*

05/2010 The role of mTOR in neurodegeneration. Texas A&M University, College Station, TX. ***Details:*** *Invited by Danna Zimmer, Ph.D.*

03/2010 Molecular interplay between Abeta, tau and mTOR: Mechanisms of neurodegeneration. University of Southern California, Los Angeles, CA. ***Details:*** *Invited by Christian Pike, Ph.D.*

05/2009 Molecular Mechanisms of Memory Loss in a Transgenic Model of Alzheimer's Disease. University of Texas Health Science Center, San Antonio, Department of Cellular and Structural Biology, San Antonio, TX. ***Details:*** *Invited by Yidong Bai, Ph.D.*

04/2009 The effect of anti-Abeta interventions on tau pathology and cognitive decline. Experimental Biology Meeting, Experimental Biology Meeting, New Orleans, LA (Invited Speaker)

04/2009 Abeta accumulation facilitates the onset and progression of tau pathology in a transgenic model of Alzheimer's disease. University of Texas Health Science Center, San Antonio, Department of Pharmacology, San Antonio, TX. ***Details:*** *Invited by Lance R. McMahon, Ph.D.*

03/2008 Abeta and Tau Interaction in a transgenic model of Alzheimer's disease. Brain Diseases and molecular machines, Paris, France. ***Details:*** *Invited by Christian Neri, Ph.D.*

03/2008 Abeta and Tau Interaction in a transgenic model of Alzheimer's disease. Servier Research Institute, Paris, France. ***Details:*** *Invited by Antoine Bril, Ph.D.*

03/2008 Abeta and Tau Interaction in a transgenic model of Alzheimer's disease. University of Catania, Italy. ***Details:*** *Invited by Agata Copani, Ph.D.*

01/2008 Abeta and Tau Interaction in a transgenic model of Alzheimer's disease. University of Texas, Health Science Center San Antonio, Department of Physiology, San Antonio, TX. ***Details:*** *Invited by David Weiss, Ph.D.*

01/2008 Abeta and Tau Interaction in a transgenic model of Alzheimer's disease. University of North Carolina, NC. ***Details:*** *Invited by William Snider, Ph.D.*

11/2007 Abeta and Tau Interactions. Texas A&M, Health Science Center, College Station, TX. ***Details:*** *Invited by William H. Griffith, Ph.D.*

10/2007 Abeta and Tau Interactions. University of Kentucky, Lexington, KY. ***Details:*** *Invited by William R. Markesbery, M.D.*

10/2007 Abeta and Tau Interactions. University of South Florida, Tampa, FL. ***Details:*** *Invited by Marcia Gordon, PhD and Huntington Potter, Ph.D.*

09/2007 Abeta immunotherapy in Alzheimer disease. The 9th Argentinian Congress of Neuropsychiatry, Argentina (Invited Speaker). ***Details:*** *Unable to attend.*

06/2007 Abeta and Tau Interactions in a Novel Transgenic Model of Alzheimer's Disease. The Jackson Laboratory, Discovery Strategies Conference, Bar Harbor, ME (Invited Speaker).

05/2007 Abeta and Tau Interactions in a Novel Transgenic Model of Alzheimer's Disease. Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland. ***Details:*** *Invited by Patrick Aebischer, MD.*

05/2007 Abeta and Tau Interactions in a Novel Transgenic Model of Alzheimer's Disease. University of California, Los Angeles, CA. ***Details:*** *Invited by John Ringman, MD.*

10/2006 Studying and Treating AD in Mice. 6th Annual Meeting of the Safety Pharmacology Society, San Diego, CA (Invited Speaker).

10/2006 M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice. 2006 Alzheimer's Disease Research Conference, Caregiver Stress, Inflammation, and Treatment Options, Irvine, CA (Invited Speaker).

04/2006 Abeta and Tau Interactions in a Novel Transgenic Model of Alzheimer's Disease. Boehringer Ingelheim, GM. ***Details:*** *Invited by Cornelia Dorner-Ciossek, Ph.D.*

03/2006 Studying and Treating Alzheimer's Disease in Mice. 37th Annual Meeting, American Society for Neurochemistry, Portland, OR (Invited Speaker)

08/2005 Studying and Treating Alzheimer's Disease in Mice. University of Dartmouth, Dartmouth, MA. ***Details:*** *Invited by TY Chang, Ph.D.*

11/2004 Studying and Treating Alzheimer's Disease in Mice. Alzheimer's disease research center. Institute for Aging and Dementia, University of California, Irvine, Irvine, CA. ***Details:*** *Invited by Carl Cotman, Ph.D.*

08/2004 Abeta Immunotherapy and its Effect on Tau Pathology. Elan pharmaceutical, San Francisco, CA. ***Details:*** *Invited by Manuel Buttini, Ph.D.*

01/2004 Abeta and Tau Interaction in a Transgenic Model of Alzheimer's Disease. Alzheimer's disease research center. Institute for aging and dementia, University of California, Irvine, Irvine, CA. ***Details:*** *Invited by Elizabeth Head, Ph.D.*

ORAL PRESENTATIONS AT MEETINGS following abstract submission:

03/2018 Necroptosis activation in Alzheimer's disease. Advances in Alzheimer's and Parkinson's Therapies, Torino, Italy.

04/2017 Mechanisms of Neuronal Loss in Alzheimer's Disease. The 13th International Conference on Alzheimer's and Parkinson's diseases, Vienna, Austria.

12/2016 mTOR/S6K1 at the crossroad between aging and Alzheimer's disease. Neurodegenerative Diseases: Biology & Therapeutics, Cold Spring Harbor Laboratories. Cold Spring Harbor, NY

07/2015 Reducing ribosomal protein S6 kinase 1 ameliorates Alzheimer's disease-like cognitive and synaptic deficits by reducing BACE-1 translation. Alzheimer's Association International Conference, Washington, DC.

03/2015 The mTOR/S6K1 pathway plays a key role in the pathogenesis of Alzheimer's disease. The 12th International Conference on Alzheimer's and Parkinson's diseases, Nice, France.

07/2014 Genetic reduction of mTOR signaling ameliorates Alzheimer's disease-related cognitive deficits and amyloid-β pathology by restoring hippocampal gene expression signature. Alzheimer's Association International Conference, Copenhagen, Denmark.

07/2013 The relationship among mTOR, Aβ and tau: Therapeutic implications for Alzheimer's disease. Alzheimer's Association International Conference, Boston, MA.

10/2012 The role of mTOR in Alzheimer's disease: Lessons from animal models. Society for Neuroscience. New Orleans, LA.

07/2012 The role of mTOR in Alzheimer's disease: Lessons from transgenic mice. Alzheimer's Association International Conference. Vancouver, British Columbia, Canada.

11/2011 Age-dependent cognitive decline typical of FTLD in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43. Society for Neuroscience Conference, Washington, DC.

03/2011 Molecular interplay between Aβ, tau and mTOR: Mechanisms of neurodegeneration. The 10th international conference on Alzheimer's and Parkinson's diseases, Barcelona, Spain.

10/2009 Rapamycin improves learning and memory in a transgenic model of Alzheimer's disease. Society for Neuroscience Conference, Society for Neuroscience, Chicago, IL.

07/2008 Blocking Abeta42 accumulation delays the onset and progression of Tau pathology and cognitive decline via CHIP: A mechanistic link between Abeta and Tau pathology. The 11th international conference on Alzheimer's disease and related disorders, Chicago, IL.

05/2008 Modulation of the Cholinergic System in the 3xTg-AD Mice. The 10th Annual Alzheimer's Disease Conference, Boston, MA.

11/2007 Reduction of Both Soluble Abeta and Tau, but not Soluble Abeta Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles. Society for Neuroscience, San Diego, CA.

07/2006 Reduction of Both Soluble Abeta and Tau, but not Soluble Abeta Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles. The 10th international conference on Alzheimer's disease and related disorders, Madrid, Spain.

11/2005 Abeta Oligomers Precede Extracellular Plaque Formation in a Transgenic Model of Alzheimer's Disease. Society for Neuroscience, San Diego, CA.

03/2005 Chronic Nicotine Administration Exacerbates Tau Pathology in a Transgenic Model of Alzheimer's disease. 7th International Conference AD/PD 2005, Sorrento, Italy.

TEACHING:

COURSE-BASED TEACHING:

Institution: University of Messina

Date	Course Name	Level	Role
10/2020 – today	Molecular Biology	Undergraduate	Instructor

Institution: Arizona State University

Date	Course Name	Level	Role
08/2018 – 12/2018	Cellular and Molecular Biology (Neu555)	Graduate	Instructor

Number of students: 28. Three credits.
This course covers basic aspects of cellular and molecular biology.

08/2018 – 12/2018	Cellular and Molecular Neuroscience (BIO476)	Undergraduate	Instructor

Number of students: 54. Three credits.
I developed this course in 2017. It covers basic cellular and molecular mechanisms related to cell biology of neurons, neuronal development, electrical properties of neurons.

01/2018 – 05/2018	BIO 400: Topics in Neuroscience	Undergraduate	Instructor

Number of students: 21. Three credits.
I have independently developed this course, which was offered for the first time in the spring semester of 2016. The course covered age-dependent neurological diseases (or a specific aspect of a disease).

01/2018 -05/2018	BIO 498: Pathologies of the Aging Brain	Undergraduate	Instructor

Number of students: 34. Three credits.
I have independently developed this course, which was offered for the first time in the spring semester of 2016. The course covered age-dependent neurological diseases (or a specific aspect of a disease).

11/2017 -12/2017	BIO189: Recitation Section	Undergraduate	Instructor

Number of students: 19. One credit.
This is a five weeks recitation course during which students were exposed to basic molecular, biochemical, and behavioral techniques in my laboratory.

08/2017 -12/2017	Cellular and Molecular Neuroscience (BIO 476)	Undergraduate	Instructor

Number of students: 31. Three credits.
I have independently developed this course, which is part of the new Neuroscience co-major at ASU. The course covers basic cellular and molecular mechanisms related to cell biology of neurons, neuronal development, electrical properties of neurons.

01/2017 – 05/2017	BIO 498: Pathologies of the Aging Brain	Undergraduate	Instructor

Number of students: 11. Three credits.
I have independently developed this course, which was offered for the first time in the spring semester of 2016. The course covered age-dependent neurological diseases (or a specific aspect of a disease).

08/2016 – 12/2016	BIO 467: Neurobiology	Undergraduate	Instructor

Number of students: 59. Three credits
This course explores the nervous system across many levels (genetic, molecular, cellular, and network). Using an active learning approach, I emphasize critical thinking and problem-solving in all evaluation exercises, including daily class participation.

01/2016 – 05/2016	BIO 498: Pathologies of the Aging Brain	Undergraduate	Instructor

Number of students: 27. Three credits.
I have independently developed this course, which was offered for the first time in the spring semester of 2016. The course covered age-dependent neurological diseases (or a specific aspect of a disease).

Institution: University of Arizona, College of Medicine-Phoenix

Date	Course Name	Level	Role
02/2014 – 03/2014	Case-based instruction: Cardiovascular	Medical School	Instructor

Number of students: 8.
Case-Based Instruction (CBI) is a teaching modality using a clinical case-based scenario. CBI provides the opportunity for students to learn new material while also applying previously learned material. CBI is extremely student-centric. CBI should develop and hone critical thinking skills, encourage discovery and identify gaps in student knowledge.

Institution: University of Texas, Health Science Center at San Antonio

Date	Course Name	Level	Role
01/2012 – 06/2013	6091-05: Molecular Physiology	Graduate	Course Director

This course provides students with the most up-to-date knowledge on the current understanding of second messengers and signaling cascades in neurons.

01/2012 – 06/2012	INTD 7002: Neurobiology of Learning and Memory	Graduate	Course Director

Overall student contact hours: 16. Total number of student enrolled: 2.

I have independently developed this course, which was offered for the first time in the spring semester of 2012. This course focuses on recent findings and topics related to the underlying aspects of the neural basis of learning and memory.

12/2010 – 06/2013	INTD 5000: Fundamentals of Biomedical Sciences	Graduate	Instructor

Overall student contact hours: 22. In 2012, I was a lecturer and gave 3 lectures of 1 hour each. In 2011 and 2012, in addition to lecturing, I was the team leader for week 6 of the course. Total number of students enrolled: 122. My responsibilities were to develop the lecture content for the week by coordinating with other team members and to lecture.

01/2010 – 06/2013	CSBL 6058: Neurobiology of Aging	Graduate	Instructor

Overall student contact hours: 16, 8 hours in 2010 and 8 in 2011. Total number of student enrolled: 9. This course focuses on recent findings and topics related to the underlying pathology of aging in the nervous system and the relationship of aging to neurodegenerative disease.

09/2009 – 06/2013	PHYL6090: Seminar	Graduate	Course Director

Overall student contact hours: 36 in class format plus 76 in presentation format. Total number of student enrolled: 128. The goal of this course is to teach students the basics of oral presentations. Students are required to give an oral presentation of their data in a formal setup. Additionally, formal class lectures are given to criticize and improve slide generation and presentation techniques. The course is offered twice a year.

01/2009 – 05/2011	INTD 5040: Molecular Cellular and Developmental Neuroscience	Graduate	Lecturer

Overall student contact hours: 21; 6 hours in 2009; 8 hours in 2010; 7 hours in 2011. Total number of students enrolled: 46. This course is intended to introduce students to a broad survey of the basics of molecular, cellular and developmental neuroscience. Current topics and concepts are discussed in discussion sessions that include student participation.

06/2009 – 12/2011	PHAR 6020 Molecular and Pharmacological Basis of therapeutics	Graduate	Instructor

Overall student contact hours: 9; 3 hours in 2009, 3 hours in 2010, 3 hours in 2011. This course provides the graduate student with current knowledge of how genetic variants can affect drug response and the potential to optimize drug therapy. Class format includes lectures, discussion of selected literature, individual student presentations, and the opportunity for the development of a mini pharmacogenetic/genomic protocol and consent form to address a clinical/biomedical question.

05/2010 - 05/2010	CSBL 6048 Biology of Aging	Graduate	Instructor

Overall student contact hours: 3; Total number of student enrolled: 10. The purpose of this course is to provide students with the most up-to-date information on the current understanding of the aging process. This advanced interdisciplinary graduate course provides an experimental understanding of the interrelated areas of aging and age-related diseases.

Institution: University of California, Irvine

Date	**Course Name**	**Level**	**Role**
10/2007 - 05/2008	BioSci: 206, Molecular	Graduate	Instructor

	Neuroscience		

Overall student contact hours: 18; This course reviews molecular and cellular mechanisms involved in neuronal function, including control of gene expression, post-transcriptional and post-translational processing, RNA and protein targeting, cell death mechanisms, and the molecular genetic basis of neurological disorders. Overview of the molecular aspects of developmental neurobiology is also included.

11/2003 - 04/2004	BioSci 113: Neurobiology Laboratory	Undergraduate	Lecturer

Overall student contact hours: 27. This is a neurobiology laboratory course in which students conduct weekly experiments covering several aspects of basic functions of the nervous system.

Institution: University of Coimbra, Portugal

Date	**Course Name**	**Level**	**Role**
02/2007 - 02/2007	Doctoral Programme in Experimental Biology and Biomedicine	Graduate	Guest Lecturer

Overall student contact hours: 10. This course focuses on the latest research in the field of neurodegenerative diseases, focusing on Alzheimer disease (AD), Parkinson disease (PD) and Huntington disease (HD).

OTHER TEACHING:

May 2018 Post Spring ASU Global Intensive Experience in Neuroscience –London, UK

This is an ASU faculty-directed study abroad program proposal focused on The Neuroscience of Sustainable Brain Plasticity at King's College London. Dr. Brian Smith and I are the directors of this initiative and traveled to the United Kingdom in May with eight ASU students enrolled in the Neuroscience concurrent major. The program lasted ten days, during which students learned about the aging of the human brain.

Visiting graduate students (Total number of students: 2)

Date	**Student**	**Institution**
04/2016 – 2019	Ramona Belfiore	Arizona State University

Ramona was an Italian Graduate Student. She came to my lab at ASU to study the progression of Alzheimer's disease-like pathology in 3xTg-AD mice.

09/2013 - 02/2014	Caterina Branca	UofA COMP

Caterina was a graduate student at the University of Brescia, Italy. She joined my laboratory in the summer of 2013 for completing a project as part of her Ph.D. studies and focused on understanding the relationship between β-blockers and Alzheimer's disease. After graduating, she joined my lab as a Postdoctoral Fellow.

Dissertations Directed for graduate students (Total number of students: 3)

Date	**Student**	**Institution**
08/2012 – 07/2016	Antonella Caccamo	University of Catania, Italy

Antonella enrolled in the international Ph.D. program at the University of Catania, Italy. She performed her thesis in my laboratory, which focused on elucidating the role of mTOR in Alzheimer's disease. Currently, she is an Assistant Research Professor in the Biodesign Institute.

07/2011-04/2014	Elena Wisely	UTHSCSA

Elena joined my laboratory in 2011 as an MD/Ph.D. student. The goal of her project was to elucidate the role of β2 adrenergic receptors in the pathogenesis of Alzheimer's disease. She defended her thesis and

graduated on March 2014. She has since completed her MD, and she is currently a pathology resident at UT Southwestern in Dallas.

11/2008-07/2013 David Medina UTHSCSA
David Medina joined my laboratory in 2008 for his graduate studies. He defended his Ph.D. thesis, which focused on elucidating the molecular link between progranulin and TDP-43 accumulation. He graduated on July 31, 2013. Currently, David is a postdoctoral fellow in the laboratory of Dr. Robert Bowser at the Barrow Neurological Institute in Phoenix.

Dissertation Proposal Committee for graduate students (Total number of students: 7)

Date	**Student**	**Institution**
08/2015 – Present	Lalitha Venkataraman	Arizona State University

Lalitha is a PhD student in the laboratory of Dr. Michael Sierks. The goal of her dissertation proposal is to develop new conformation-specific antibodies for neurodegenerative diseases.

09/2012 – 06/2013 Teresa Evans UTHSCSA
Teresa was a Ph.D. student in the laboratory of Dr. Holly Van Remmen, Department of Cell and Structural Biology/Barshop Institute for Longevity and Aging Studies. The goal of her dissertation proposal was to assess the role of traumatic brain injury in amyotrophic lateral sclerosis.

09/2012 – 06/2013 Wenrui Ye UTHSCSA
Wenrui was a Ph.D. student in the laboratory of Dr. Brent Thompson. The goal of her dissertation proposal was to examine disturbance in the fetal serotonergic nervous system induced by MNR, which may predispose the offspring to the psychiatric disorders reported in IUGR offspring.

03/2011 - 04/2012 Yael Edrey UTHSCSA
Yael was a Ph.D. student in the laboratory of Dr. Rochelle Buffenstein, Department of Physiology/Barshop Institute for Longevity and Aging Studies. She successfully defended in April 2012.
Title: The longest-living rodent as a model for neurodegeneration and Alzheimer's disease.

07/2009 – 11/2012 Yu Tao UTHSCSA
Yu Tao was a Ph.D. student in the laboratory of Dean David Weiss. She successfully defended on November 2012.
Title: Defining the role of GABAergic transmission in neurogenesis in adult brain.

03/2009 – 12/2012 Leo Chang UTHSCSA
Leo was a Ph.D. student in the laboratory of Dr. Benjamin Eaton in the Department of Physiology. He successfully defended in December 2012.
Title: Molecular characterization of DARF2 in the Drosophila nervous system.

03/2009 - 08/2011 Si-Eun Yoo UTHSCSA
Si-Eun obtained a Master of Science in August 2011.
Title: New insights into the in vivo role of lipid peroxidation in adult mice using novel Gxp4 knockout mouse model.

Qualifying Exam Committee for graduate students (Total number of students: 4)

Date	**Student**	**Institution**
06/2012 – 09/2012	Jennifer Parrott	UTHSCSA

Jennifer was a Ph.D. student in the laboratory of Dr. Jason O'Connor, Department of Pharmacology.
Title: Modulating the balance of kynurenine pathway metabolites to attenuate Alzheimer's disease comorbid depressive-like behaviors, neuropathology, and cognitive decline.

04/2012 - 04/2012 Danielle Victor UTHSCSA

Danielle was an MD/Ph.D. student in the laboratory of Dr. Brian Herman, Department of Cellular and Structural Biology/Barshop Institute for Longevity and Aging Studies.
Title: Peroxynitrite induces mitochondrial protein nitration and dysfunction in the aging heart

02/2011 - 03/2011 Teresa Evans UTHSCSA
Teresa was a Ph.D. student in the laboratory of Dr. Holly Van Remmen, Department of Cellular and Structural Biology/Barshop Institute for Longevity and Aging Studies.
Title: Cell and disease-specific modulation of autophagy following traumatic brain injury.
04/2010 - 07/2010 Rene Santacruz UTHSCSA
Rene was a Ph.D. student in the laboratory of Dr. Senlin Li, Department of Medicine.

Rotation Graduate Student Supervision (total number of students 15)

Date	**Student**	**Institution**
08/2017 – 10/2017	Sara Knowles	Arizona State University

During her rotation as first-year Ph.D. student in the Neuroscience program, Sara learned how to test cognitive function in mice.

05/2014 – 07/2014 Lalitha Venkataraman Arizona State University
During her rotation as first-year Ph.D. student in the Neuroscience program, Lalitha assessed the degree of TDP-43 pathology in a new mouse model of FTLD.

11/2012 – 12/2012 Rene Solano Fonseca UTHSCSA
During his rotation, Rene learned how to perform stereotaxic injection into the mouse brain.

09/2012 – 11/2012 Brian Stoveken UTHSCSA
During his rotation, Brian conducted immunohistochemical experiments to map the regional and temporal progression of Aβ and tau pathology in a mouse model of Alzheimer's disease.

02/2012 – 03/2012 Juan Xiong UTHSCSA
During her rotation, Juan learned basic cell culture techniques.

01/2012 – 02/2012 Paul Anthony Martinez UTHSCSA
During his rotation, Anthony learned how to use the Freeze Monitor to conduct contextual fear conditioning experiments. Currently, he is a Ph.D. student in the laboratory of Dr. Randy Strong, Department of Pharmacology.

11/2011 – 12/2011 Shauna Hill UTHSCSA
During her rotation, Shauna worked with David Medina, a graduate student in the laboratory, to establish the effect on increasing mitochondrial function on Alzheimer's disease pathogenesis.

09/2011 - 11/2011 Saul Jaime UTHSCSA
During his rotation, Saul learned how to slice a mouse brain and perform immunohistochemical experiments. He was a first-year Ph.D. student in the IMGP program.

09/2010 - 11/2010 Rebekah Mahoney UTHSCSA
During her rotation, Rebekah learned how to perform PCR and Western blot experiments. Rebekah was a second year Ph.D. student in the laboratory of Dr. Benjamin Eaton, Department of Physiology.

05/2010 - 07/2010 Elena Wisely UTHSCSA
During her rotation in my laboratory, Elena learned how to perform Western blot experiments. She was a second-year MD/Ph.D. student in my laboratory.

11/2009 - 12/2009 Walter Holbein UTHSCSA

During his rotation, Walter learned how to perform intracranial injections in mice. Walter was a PhD student in the laboratory of Dr. Glenn Toney, Department of Physiology.

11/2009 - 12/2009 Chrislie Starr UTHSCSA
During her rotation, Chrislie learned how to extract proteins from the mouse brain. She also learned how to perform Western blot experiments.

07/2009 - 08/2009 Celest Austin UTHSCSA
During her rotation, Celest learned how to purify RNA from mouse brain and perform qPCR. She did her Ph.D. thesis in the laboratory of Dean David Weiss, Department of Physiology.

01/2009 - 02/2009 Daniel Pulliam UTHSCSA
During his rotation, Daniel learned how to perform Western blot experiments. He did his Ph.D. thesis in the laboratory of Dr. Holly Van Remmen.

11/2008 - 12/2009 David Medina UTHSCSA
David rotated in my laboratory for two different periods, 11/2008-12/2008 and 02/2009-04/2009. During these rotations, David learned how to extract proteins from the mouse brain, how to perform western blot experiments and how to prepare primary neuronal culture.

Undergraduate Honors Thesis, Primary Mentor and Chair (Total number of students: 7)

Date	**Student**	**Institution**
01/2022 – Today	Martina Giordano	University of Messina
01/2018 – 2019	Marieke Sorge	Arizona State University
01/2018 – 2019	Aronee Hossain	Arizona State University
01/2018 – 2019	Tasha Parekh	Arizona State University
08/2017 – 2019	Likith Surendra	Arizona State University

Likith joined my laboratory in his sophomore year and has worked in the lab under my supervision since. His project is focused on dissecting the role of PRAS40 in learning and memory.

08/2015 – 2019 An Tran Arizona State University
An joined my laboratory in her sophomore year and has worked in the lab under my supervision since. Her project is focused on identifying the role of tau in the adult brain. She is scheduled to defend her honors thesis on April 12th, 2018.

08/2015 – 2019 Prakriti Shukla Arizona State University
Prakriti joined my laboratory in her sophomore year and has worked in the lab under my supervision since. Her project is focused on dissecting the role of S6K1 in old 3xTg-AD mice. She defended her honors thesis on March 22nd, 2018.

08/2015 – 2019 Patrick Sarette Arizona State University
Patrick joined my laboratory in his sophomore year. In January 2018, he successfully defended his honors thesis, titled “Elucidating the Effects of PRAS40 on Learning and Memory”. **He has been accepted into the University of Arizona, College of Medicine, Phoenix Medical School and will start in July 2018.**

Undergraduate Honors Theses, Committee Member (total number of students: 2)

Date	**Student**	**Institution**
05/2016 – 12/2017	Justin Palmer	Arizona State University

Justin was an undergraduate student enrolled in Barrett, The Honors College. I served as a co-chair of his dissertation committee together with Dr. Bimonte-Nelson.

01/2017 – 05/2017 Jason Ma Arizona State University

Jason was an undergraduate student enrolled in Barrett, The Honors College. His primary mentor was Dr. Brian Smith. I served as a member of his dissertation committee.

Other Undergraduate Student Supervised (total number of students: 7)

Date	Student	Institution
08/2015 – 12/2016	Christopher Negrich	Arizona State University

Chris' project was to determine the biochemical changes in 3xTg-AD mice following traumatic brain injury.

06/2014 – 08/2014	Owen Steinwall	BSHRI

Owen joined my laboratory as an intern during summer. His project was to quantify the regional and temporal progression of Aβ and tau pathology in 3xTg-AD mice.

06/2012 – 06/2013	Angelica Salinas	UTHSCSA

Angelica joined my laboratory as part of a South Texas Advanced Research Training (START-UP) program at UTHSCSA. The goal of her project was to characterize the regional and temporal progression of Aβ and tau pathology in the 3xTg-AD mice.

06/2011 - 07/2011	Amanda Riojas	UTHSCSA

Amanda joined my laboratory for a summer internship as part of the Physiology Undergraduate Research Experience. The goal of her project was to elucidate the molecular basis underlying the gender difference in Aβ pathology in a mouse model of Alzheimer's disease.

08/2010 – 08/2011	Asta Vasalauskaite	UTHSCSA

Asta was a participant in the Ulster Undergraduate Research Program, a partnership between the Department of Physiology and The University of Ulster, Coleraine to provide Ulster second-year undergraduate students with a research internship at UTHSCSA as part of their B.Sc. Honors degree in Biomedical Science. During her time in my laboratory, Asta learned how to perform PCR and Western blot experiments and participated in a project focused on elucidating the role of mTOR in the pathogenesis of Alzheimer's disease.

01/2010 - 01/2011	Andrea Magri	UTHSCSA

Andrea was a visiting undergraduate student from Italy, who spent one year in my laboratory. The goal of his project was to determine the role of mTOR in the tau-mediated neurodegeneration. Currently, Andrea is postdoctoral fellow at the University of Catania, Italy.

11/2008 - 08/2009	Fiona Thornton	UTHSCSA

Fiona was a participant in the Ulster Undergraduate Research Program, a partnership between the Department of Physiology and The University of Ulster, Coleraine to provide Ulster second-year undergraduate students with a research internship at UTHSCSA as part of their B.Sc. Honors degree in Biomedical Science. During her time in my laboratory, Fiona learned how to perform PCR, immunohistochemistry and Western blot experiments and participated in a project focused on elucidating the role of rapamycin in the pathogenesis of Alzheimer's disease.

High School Students Supervision (total number of students: 1)

Date	Name	Institution
05/2015 – 2018	Nikhil Dave	Arizona State University

Nik is a Horizon Honors High School Student who joined my laboratory in 2015 as a volunteer. He has contributed to several projects in the laboratory. Currently, he is a senior in high school and has already been accepted into multiple universities. **He also was recently awarded the Flinn Scholarship.**

Post-Doctoral Supervision (Total number of postdoctoral fellows: 9)

Date	Name	Institution
02/2022 -Today	Laura De Plano, Ph.D.	University of Messina
06/2017 – 2019	Emily Turner, Ph.D.	Arizona State University

Dr. Turner is a Postdoctoral Fellow in my laboratory. Currently, she is working on assessing the role of necroptosis in Alzheimer's disease.

12/2016 – 2019 Rasika Vartak, Ph.D. Arizona State University
Dr. Vartak is a Postdoctoral Fellow in my laboratory. Currently, she is working on assessing the role of S6K1 on tau.

09/2014 – 2019 Ramon Velazquez, Ph.D. Arizona State University
Dr. Velazquez is a Postdoctoral Fellow in my laboratory. His project focuses on assessing whether diet-induced epigenetic changes in a mouse model of AD are transmitted from generation to generation.

02/2014 - 02/2018 Caterina Branca, Ph.D. Arizona State University
Dr. Branca was a Postdoctoral Fellow in my laboratory. She studied the role of RIPK1 in Alzheimer's disease.

11/2016 – 05/2017 Rizwan Haque, Ph.D. Arizona State University
Dr. Haque was a Postdoctoral Fellow in my laboratory. His project was focused on identifying the molecular mechanisms leading to hyperactive mTOR in Alzheimer's disease.

06/2014 – 12/2015 Joshua Talboom, Ph.D. Arizona State University
Dr. Talboom was a Postdoctoral Fellow in my laboratory. He is using innovative approaches to restore cognition in a mouse model of Alzheimer's disease by remotely stimulating selective neuronal networks. Currently, Josh is a postdoctoral fellow in the laboratory of Dr. Matt Huentelman at the Translational Genomics Institute in Phoenix.

02/2014 – 10/2014 Emma Farrell, Ph.D. BSHRI
Dr. Farrell was a Postdoctoral Fellow. Her project focused on using pharmacological approaches to reduce mTOR signaling in Alzheimer's disease. Currently, she is a Chemistry Lecturer at Arizona State University West.

04/2012-12/2013 Miranda Orr, Ph.D. UTHSCSA
Dr. Orr was a Postdoctoral Fellow in my laboratory. The goal of her project was to determine whether facilitating endogenous compensatory mechanisms in the brain might improve learning and memory deficits in Alzheimer's disease. Currently, she is an Instructor in the Department of Pharmacology at the University of Texas Health Science Center at San Antonio and a Scientist at the Veteran Affair Hospital in San Antonio.

06/2010-12/2011 Monica Maldonado, Ph.D. UTHSCSA
Dr. Maldonado was a Postdoctoral Fellow in my laboratory. The goal of her project was to elucidate the role of chaperone-mediated autophagy in Aβ and tau accumulation. Currently, she is an Editor for the American Journal Experts.

Employee Supervision (Total number of employee: 9)

Date **Employee** **Institution**

11/2018 – 2019 Austin Vural Arizona State University
Austin is a Research Associate and provides technical support to other lab members.

02/2016 – 2019 Wendy Winslow Arizona State University
Wendy is the lab manager and oversees the entire mouse colony.

02/2015 – 2018 Eric Ferreira BSHRI/ASU
Eric is a Research Associate and provides technical support to other lab members.

10/2016 – 08/2017 Alexis Rodin Arizona State University

08/2015 – 01/2016	Mario Moreno	Arizona State University
09/2013 – 08/2015	Darren Shaw	BSHRI
09/2014 – 07/2015	Aaron Walter	BSHRI
09/2013 – 09/2014	Lauren Hartman	BSHRI
03/2012 – 10/2012	Laura Nelon	UTHSCSA
11/2008 – 08/2012	Smita Majumder	UTHSCSA

PATENTS:

Patent Date	Details
07/2016	Necroptosis Signaling as a Therapeutic Target for Alzheimer's disease. Provisional Application No. 62356983.
12/2011	Treatment of neurodegenerative diseases with CREB-binding protein. Provisional Application No. 61/568,458, Co-Inventor: Antonella Caccamo
11/2009	Inhibition of Mammalian Target of Rapamycin. Patent No. 13/128,800, Co-Inventor(s): Zelton Dave Sharp, John R. Strong, Veronica Galvan, Herbert G. Wheeler

SERVICE:

Service to the University of Catania

Dates	Description	Role
03/2022 -04/2022	Selection board for Ph.D. thesis defenses for the International Ph.D. program in Neuroscience	Committee Member

Service to the University of Messina

Dates	Description	Role
06/2021 – 07/2021	Competition for the selection of researchers type A, BIO/11	Committee Member

Service to Sapienza University, Rome

Dates	Description	Role
11/2021 – 12/2021	Competition for the selection of researchers type A, BIO/12	Committee Member

Service to Arizona State University

Dates	Description	Role
08/2017 – 2019	SOLS Graduate Program Committee	Committee Member
08/2017 – 2019	CLAS Graduate Committee	Committee Member
07/2017 – 2019	Interdisciplinary Graduate Program in Neuroscience	Director
01/2017 – 2019	Arizona Wellbeing Commons, Starring committee	Committee Member
01/2017 – 2019	Arizona Wellbeing Commons, Neuroscience division	Director
05/2016 – 2019	Biodesign Institute Personnel Committee	Committee Member

01/2017 – 04/2017	Poster Session –Biodesign Scientific Retreat	Committee Chair
12/2016 – 07/2017	Molecular and Cellular Biology Graduate Program –Executive Committee	Committee Member
02/2016 – 05/2017	Neuroscience Committee to create a Neuroscience Major	Committee Member
09/2015 – 06/2017	Interdisciplinary Graduate Program in Neuroscience –Executive Committee	Committee Member

Service to the Banner Sun Health Research Institute

Dates	Description	Role
11/2013 – 07/2015	IACUC Committee	Committee Member

Service to the University of Arizona, College of Medicine-Phoenix

Dates	Description	Role
03/2014 – 07/2015	Curricular Evaluation work group for the Neuromusculoskeletal Block.	Committee Member
09/2013 – 07/2015	Early Stage Investigator Committee	Committee Member

Service to the University of Texas Health Science Center at San Antonio

Dates	Description	Role
03/2013 – 06/2013	Fundamentals of Biomedical Science review committee	Committee Member

The objective of this committee is to modify the INTD5000 core course based on students and faculty feedback from the previous year.

12/2012 - 06/2013 Faculty Search Committee Committee Member
The objective of this committee is to recruit a new Faculty member for the Department of Physiology.

09/2011 - 06/2013 Committee on Graduate Studies for the MCIP track Committee Member
The Molecular, Cellular and Integrative Physiology COGS is responsible for monitoring students' academic progress in educational and research activities, attesting eligibility for admission to Ph.D. candidacy.

08/2011 - 06/2013 Library Committee Committee Member
The committee serves in consultative and advisory capacity to the President and Vice President for Academic Administration and to work with and assist the Director of the Library in making recommendations for Library practices and procedures. To review and advise on the development of priorities in areas that have an impact on academic efficiency and effectiveness to ensure that the services provided by the Library reflect the needs and interests of the academic community.

09/2012-12/2012 Department of Physiology Faculty Compensation (XYZ) Plan Committee Committee Member
The task of the committee is to undertake candid, unbiased and constructive deliberations, keeping in view the high standards that we expect of our faculty, to create a reward mechanism for the Physiology faculty and thus help ensure the future success of the Department of Physiology.

09/2012-12/2012 Department of Physiology: Task Force Committee Committee Member
The principal charges of this committee are: (i) Faculty Recruitment; (ii) Invigorating interactions among existing faculty; (iii) Invigorating interactions among students.

09/2011-07/2012 Recruitment Coordinator for MCIP Track (School level) Committee Member
The primary role of the committee is to refine, prioritize and execute the findings of the School Recruitment Committee. The committee organizes the recruitment weekends for the IMGP applicants.

09/2011-07/2012 Recruitment Coordinator for MCIP Track (Track level) Chair
This committee will develop strategies to help to increase the quality of students applying to the IMGP program and enrolling into the MCIP track.

04/2011-06/2012 Barshop Advisory Committee for Biomedical Research Committee Member
The committee discusses the progress of the Barshop Institute concerning current programs in aging and future directions. It plays an essential function in gaining input from across the research community concerning research and training programs in basic biomedical research in aging.

03/2011-03/2012 South Texas Research Facility Neuroscience Director Search Committee Committee Member
The objective of this committee is to recruit a Director for the Neuroscience area of the South Texas Research Facility.

09/2009-09/2010 IMGP admission and distribution committee member Committee Member
The goal of this committee is to review students' application for the IMGP program and make recommendations to the Dean's office as to the students that should be accepted. The committee members also serve as mentors for first-year graduate students in the IMGP program.

09/2009-05/2012 Organizing the Barshop Seminar Series Committee Member
The objective of this committee is to coordinate and oversee the Barshop seminar series, a weekly event throughout the academic year.

07/2009-02/2010 Faculty Search Committee Committee Member
The objective of this committee is to recruit a new Faculty member for the Department of Physiology.

11/2008-11/2008 Presenting at the Postdoctoral seminar series Presenter

Service to the profession:

Dates	**Description**	**Role**
12/2016 – Present	*Aging Cell*	Supervising Editor
05/2016 – 2019	Arizona Alzheimer's Consortium Internal Scientific Advisory Committee	Committee member
04/2016 – Present	*Brain Research*	Senior Editor
07/2012 - 2013	*Neuroscience Journal*	Editorial Board Member
01/2010 - 2013	*Frontiers in Psychiatry*	Review Editor

01/2006-Present Journal Review Service Ad Hoc Reviewer
Science, Nature Reviews Neuroscience, Neurobiology of Aging, The FASEB Journal, Journal of Neuroscience, Proceedings of the National Academy of Science, Aging Cell, Journal of Neuroscience Methods, Frontiers in Bioscience, Journal of Alzheimer's disease, NeuroMolecular Medicine, Journal of Neuroinflammation, Cell Death and Differentiation, Journal of Cellular and Molecular Medicine, Journal of Neurochemistry, PloSONE, Brain Research, Journal of Comparative Neurology, Current Alzheimer's Research, European Journal of Neuroscience, Molecular Neurodegeneration, Current Enzyme Inhibition. Future Neurology, Acta Neuropathologica, Biological Psychiatry, Neurochemistry International, Molecular Psychiatry, American Journal of Pathology, Nature Communications, Nature Neuroscience.

Dates	**Granting Agency**	**Role**

07/2018 – 2020	NIH Cellular and Molecular Biology of Neurodegeneration Study Section	Permanent Member
10/2011 - Present	Alzheimer's Drug Discovery Foundation	Permanent Member
04/2008 - Present	Alzheimer's Association (USA)	Ad Hoc Reviewer
10/2017	NIH Neurological Sciences and Disorders B	Ad Hoc Reviewer
10/2017	NIH Neural Oxidative Metabolism and Death Study Section	Ad Hoc Reviewer
06/2017	NIH Special Emphasis Panel/ ZRG1 MDCN-T(56)	Committee Member
11/2016	NIH Special Emphasis Panel/ ZRG1 MDCN-T(56)	Committee Member
09/2016	Darrel K Royal Research Fund for Alzheimer's disease	Ad Hoc Reviewer
06/2016	NIH Special Emphasis Panel/ ZRG1 MDCN-T(56)	Committee Member
03/2016	NIH Special Emphasis Panel/ ZRG1 MDCN-T(56)	Committee Member
07/2015	Texas Alzheimer's Research and Care Consortium	Ad Hoc Reviewer
04/2015	NIH Special Emphasis Panel/Scientific Review group	Committee Member
10/2014	NIH Special Emphasis Panel for Alzheimer's Disease Research Center applications	Committee Member
06/2014	NIH Cellular and Molecular Biology of Neurodegeneration Study Section	Ad Hoc Reviewer
02/2014	NIH Cellular and Molecular Biology of Neurodegeneration Study Section	Hoc Reviewer
05/2013 – 04/2014	American Federation for Aging Research Review Panel	Member
06/2013	NIH Chronic Dysfunction and Integrative Neurodegeneration study section	Ad Hoc Reviewer
01/2009 - 07/2013	Alzheimer's Society (UK)	Reviewer
07/2012	Biotechnology and Biological Sciences Research Council (UK)	Ad Hoc Reviewer
06/2012	NIH Molecular Neurogenetics Study Section	Ad Hoc Reviewer
03/2012	NIH Human Cell Reprogramming for Aging and Alzheimer's Disease	Committee Member
01/2012	NIH Translational Research in Aging, ZAG1 ZIJ-1	Ad Hoc Reviewer
09/2011	NIH Special Emphasis Panel/Scientific Review Group	Ad Hoc Reviewer
09/2011	NIH Molecular Neurogenetics study section	Ad Hoc Reviewer
08/2010	US Department of Veterans Affairs RR&D	Ad Hoc Reviewer
07/2010	Dutch Internationale Stichting Alzheimer Onderzoek	Ad Hoc Reviewer
04/2010 – 07/2012	Reviewer for the Institute for Integration of Medicine and science clinical and translational science award.	Ad Hoc Member
03/2009 - 04/2010	Israel Science Foundation	Reviewer
03/2009 - 04/2010	Medical Research Council, London (United Kingdom)	Reviewer
02/2009 - 03/2010	U.S.-Israel Binational Science Foundation	Reviewer
01/2005	International Alzheimer's Research Foundation (Italy)	Reviewer

PROFESSIONAL AFFILIATIONS:

Dates	Organization
01/2002 – 12/2015	Society for Neuroscience
04/2013 – 03/2014	New York Academy of Sciences

PROFESSIONAL DEVELOPMENT:

Date	Description
02/26/2018	CV and Personal Statement Workshop. Arizona State University.
04/18/2017	Developing the New Generation of Researchers: Mentoring Graduate Students and Postdocs thought the IDP workshop. Arizona State University.

09/30/2016 Peer Teaching Evaluation Workshop. Arizona State University.

09/25/2013 Case-Based Instruction (CBI) Curriculum Training at the University of Arizona, College of Medicine-Phoenix.

04/24/2012 Academic Center for Excellence in Teaching, University of Texas Health Science Center at San Antonio. Teaching Skills Workshops – Reflection in action

04/10/2012 Academic Center for Excellence in Teaching, University of Texas Health Science Center at San Antonio. Teaching Skills Workshops – Unlearning in order to learn

03/20/2012 Academic Center for Excellence in Teaching, University of Texas Health Science Center at San Antonio. Teaching Skills Workshops - Critical Thinking

11/10/2011 NeuroStereology Workshop. The goal of the workshop is to teach a small group of research scientists how to design, supervise, and critically evaluate stereological studies of the nervous system.

02/18/2009 Case-Based Teaching Workshop. Presented by Jennifer Peel at University of Texas Health Science Center at San Antonio.

02/04/2009 Promotion and Tenure Faculty, Workshop on promotion and tenure for tenure-track faculty at UTHSCSA.

COMMITTEES (OTHER):

DEPARTMENT

Dates	Committee	Role
01/2009-06/2013	Postdoctoral travel award selection committee, UTHSCSA	Member
02/2010-01/2011	Graduate Student Task Force Committee, UTHSCSA	Member

SERVICE TO THE PUBLIC:

Dates	Description	Role
10/2012	SFN-sponsored Alzheimer's disease social, New Orleans, LA.	Chair
03/2010-03/2010	Brain Bowl 2010 directed by David Morilak, Ph.D.	Judge